|
Evaluating antitumor effect of a novel hydrazide derivative in mammalian mice model
|
Zahra Kooshafar   , Mona Salimi , Ameneh Javid |
|
|
|
Abstract: (4200 Views) |
| Introduction: One of the major problems of breast cancer is unwanted side effects and tumor resistance to the available chemotherapeutics. Therefore, there is always a need toward finding new anticancer agents with limited toxicity and less multidrug resistance of cancer cells. Literature studies on hydrazones have shown that these derivatives have a wide variety of biological activities including antitumoral effects. Thus, the aim of this study was to examine the antitumor effect of a novel hydrazide derivative [2- (phenlthoi) benzoid acid (5-nitor-2-furyline) hydrazid (Compound A)] in mammalian mice model.
Materials and Methods: We injected 106 4T1 cells into mammary fat pad of 6-8 week old female BALB/c mice to establish the syngenic breast cancer model. Following, the apperance of brerast tumors, the compound A was injected (i.p.) at doses of 1, 10 and 50 mg/kg per days for three weeks.
Results: ung metastasis was observed after 28 days of cell injection, which was confirmed by histopathological experiments. Compound A treated mice group significantly reduced primary tumor growth at all tested doses however, the dose of 10 mg/kg was the most effective in reducing the tumor size. Histopathologic data showed that the regression of tumor growth was associated with extensive inflammation. The dose of 10 mg/kg compound A reduced size of secondary lung tumor and caused necrosis.
Conclusion: Collectively, the great potential exhibited by compound A could make it a promising chemotherapeutic candidate for breast cancer. |
|
| Keywords: Breast Cancer, Hydrazide, BALB/c Mice, Histopathology |
|
|
Full-Text [PDF 1538 kb]
(859 Downloads)
|
Type of Study: Research |
Subject:
General
Received: 2017/07/25 | Accepted: 2018/02/6 | Published: 2018/06/22
|
|
|
|
|
|
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
